ANEUVO to Showcase Breakthrough Neuromodulation Device ExaStim® at MEDICA 2024
- Novel Device with FDA Breakthrough Device Designation to Treat Chronic Spinal Cord Injuries,
- Attendees Invited to Visit Booth Hall 10 / H44 to Explore FDA Breakthrough Device Designation Technology
The next step in restoring mobility and independence for individuals with chronic spinal cord injuries is almost here. ANEUVO, a company dedicated to improving lives through innovative therapies, will showcase its ExaStim neuromodulation device at the MEDICA 2024 conference. ExaStim is a portable, customizable, non-invasive solution designed to help people with chronic spinal cord injuries regain motor function. Currently part of the ASPIRE™ clinical trial in the U.S., the device has been granted FDA Breakthrough Device Designation, reflecting the early confidence in the safety and efficacy of the device as it aims to bring renewed hope to individuals living with SCI and their families.
Early Clinical Results Show Promise
In a pilot study involving participants with chronic SCI, ExaStim has shown the potential to safely enhance upper limb function. Nine out of twelve participants completed the study, with improved motor scores and injury classifications. Notably, some participants experienced functional gains, such as advancing from C4 to C5 and C6 to C7 in the neurological level of injury, offering a previously unattainable step forward in their recovery.
While these results are promising, the variability in participant outcomes highlights the importance of further study in the ongoing ASPIRE trial.
“Rehabilitation for chronic spinal cord injuries remains a complex, global challenge, one that ANEUVO is dedicated to exploring novel approaches, like neuromodulation, to solving,” said Dr. Yi-Kai Lo, CEO and co-founder of ANEUVO. “As we near the completion of our clinical research, ANEUVO will soon embark on a new journey, bringing us one step closer to improving the lives of countless individuals living with chronic SCI.”
Meet the Innovators and Explore the Technology Firsthand
MEDICA attendees are invited to visit Booth Hall 10 / H44, where they can see ExaStim up-close, meet its creator, Dr. Yi-Kai Lo, and engage with the ANEUVO team. This display will allow attendees to see the device up close and better understand its real-world applications.
Pioneering a New Path in SCI Rehabilitation
ExaStim is not a cure, but it represents a critical advancement in the treatment of chronic spinal cord injuries. With the potential for significant mobility improvements in weeks vs months, ExaStim could open new pathways for continued recovery without the risks of brain surgery.
With every old nerve pathway reactivated by ExaStim’s programmable electrode array, a new beacon of hope is lit for the end user, their caretakers, and their families.
Join us at MEDICA 2024 – November 11-14, 2024 – to learn more about the technology behind the ExaStim Stimulation System and explore its potential impact on the future of SCI rehabilitation.
On-Site Contact:
Katie Velez
Vice President, Global Marketing and Strategy
kvelez@aneuvo.com
Jordan Sherman
